Literature DB >> 33027527

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.

Neeraj Saini1, Qaiser Bashir1, Denái R Milton2, Guilin Tang3, Ruby Delgado1, Gabriela Rondon1, Uday R Popat1, Chitra M Hosing1, Yago Nieto1, Partow Kebriaei1, Amin M Alousi1, Rohtesh Mehta1, Samer Srour1, Issa F Khouri1, Donna M Weber4, Sheeba K Thomas4, Hans C Lee4, Krina K Patel4, Robert Z Orlowski4, Richard E Champlin1, Muzaffar H Qazilbash1.   

Abstract

Entities:  

Year:  2020        PMID： 33027527      PMCID： PMC7556152          DOI： 10.1182/bloodadvances.2020002590

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  10 in total

1.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

2.  Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.

Authors:  Timothy Madden; Marcos de Lima; Neil Thapar; John Nguyen; Soonja Roberson; Daniel Couriel; Betty Pierre; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

3.  Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

Authors:  Juan José Lahuerta; Carlos Grande; Joan Blade; Joaquín Martínez-López; Javier de la Serna; Adrian Alegre; Laraña Jose Garcia; Dolores Caballero; Javier de la Rubia; Julián Marín; Cristina Perez-Lopez; Anna Sureda; Antonio Escudero; Rafael Cabrera; Eulogio Conde; Juan Carlos García-Ruiz; Katty Pérez-Equiza; Fernado Hernandez; Luis Palomera; Angel León; Pilar Giraldo; Carlos Solano; Joan Bargay; Miguel Jesús San
Journal:  Leuk Lymphoma       Date:  2002-01

4.  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Authors:  Edward A Stadtmauer; Marcelo C Pasquini; Beth Blackwell; Parameswaran Hari; Asad Bashey; Steven Devine; Yvonne Efebera; Siddharta Ganguly; Cristina Gasparetto; Nancy Geller; Mary M Horowitz; John Koreth; Kristin Knust; Heather Landau; Claudio Brunstein; Philip McCarthy; Courtney Nelson; Muzaffar H Qazilbash; Nina Shah; David H Vesole; Ravi Vij; Dan T Vogl; Sergio Giralt; George Somlo; Amrita Krishnan
Journal:  J Clin Oncol       Date:  2019-01-17       Impact factor: 44.544

5.  Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Authors:  Michele Cavo; Francesca Gay; Meral Beksac; Lucia Pantani; Maria Teresa Petrucci; Meletios A Dimopoulos; Luca Dozza; Bronno van der Holt; Sonja Zweegman; Stefania Oliva; Vincent H J van der Velden; Elena Zamagni; Giuseppe A Palumbo; Francesca Patriarca; Vittorio Montefusco; Monica Galli; Vladimir Maisnar; Barbara Gamberi; Markus Hansson; Angelo Belotti; Ludek Pour; Paula Ypma; Mariella Grasso; Alexsandra Croockewit; Stelvio Ballanti; Massimo Offidani; Iolanda D Vincelli; Renato Zambello; Anna Marina Liberati; Niels Frost Andersen; Annemiek Broijl; Rossella Troia; Anna Pascarella; Giulia Benevolo; Mark-David Levin; Gerard Bos; Heinz Ludwig; Sara Aquino; Anna Maria Morelli; Ka Lung Wu; Rinske Boersma; Roman Hajek; Marc Durian; Peter A von dem Borne; Tommaso Caravita di Toritto; Thilo Zander; Giorgina Specchia; Anders Waage; Peter Gimsing; Ulf-Henrik Mellqvist; Marinus van Marwijk Kooy; Monique Minnema; Caroline Mandigers; Anna Maria Cafro; Angelo Palmas; Susanna Carvalho; Andrew Spencer; Mario Boccadoro; Pieter Sonneveld
Journal:  Lancet Haematol       Date:  2020-04-30       Impact factor: 18.959

6.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

7.  Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

Authors:  Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Carlos Grande; Javier de la Rubia; Laura Rosiñol; Anna Sureda; José García-Laraña; Joaquín Díaz-Mediavilla; Miguel T Hernández-García; Dolores Carrera; Joan Besalduch; Felipe de Arriba; Albert Oriol; Lourdes Escoda; Javier García-Frade; Concepción Rivas-González; Adrían Alegre; Joan Bladé; Jesús F San Miguel
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

8.  Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

Authors:  Nisha S Joseph; Jonathan L Kaufman; Madhav V Dhodapkar; Craig C Hofmeister; Dhwani K Almaula; Leonard T Heffner; Vikas A Gupta; Lawrence H Boise; Sagar Lonial; Ajay K Nooka
Journal:  J Clin Oncol       Date:  2020-04-16       Impact factor: 44.544

9.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Authors:  Pieter Sonneveld; Hervé Avet-Loiseau; Sagar Lonial; Saad Usmani; David Siegel; Kenneth C Anderson; Wee-Joo Chng; Philippe Moreau; Michel Attal; Robert A Kyle; Jo Caers; Jens Hillengass; Jesús San Miguel; Niels W C J van de Donk; Hermann Einsele; Joan Bladé; Brian G M Durie; Hartmut Goldschmidt; María-Victoria Mateos; Antonio Palumbo; Robert Orlowski
Journal:  Blood       Date:  2016-03-21       Impact factor: 22.113

10.  Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Authors:  Qaiser Bashir; Peter F Thall; Denái R Milton; Patricia S Fox; Jitesh D Kawedia; Partow Kebriaei; Nina Shah; Krina Patel; Borje S Andersson; Yago L Nieto; Ben C Valdez; Simrit Parmar; Gabriela Rondon; Ruby Delgado; Chitra Hosing; Uday R Popat; Betul Oran; Stefan O Ciurea; Pei Lin; Donna M Weber; Sheeba K Thomas; Hans C Lee; Elisabet E Manasanch; Robert Z Orlowski; Loretta A Williams; Richard E Champlin; Muzaffar H Qazilbash
Journal:  Lancet Haematol       Date:  2019-03-22       Impact factor: 30.153
  10 in total
  1 in total

Review 1.  Pathogenesis and treatment of multiple myeloma.

Authors:  Peipei Yang; Ying Qu; Mengyao Wang; Bingyang Chu; Wen Chen; Yuhuan Zheng; Ting Niu; Zhiyong Qian
Journal:  MedComm (2020)       Date:  2022-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.